134 related articles for article (PubMed ID: 25876971)
21. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
[TBL] [Abstract][Full Text] [Related]
22. Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
Kai Y; Amatya VJ; Kushitani K; Kambara T; Suzuki R; Tsutani Y; Miyata Y; Okada M; Takeshima Y
Histopathology; 2019 Mar; 74(4):545-554. PubMed ID: 30329165
[TBL] [Abstract][Full Text] [Related]
23. The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: a study of 20 cases.
Winstanley AM; Landon G; Berney D; Minhas S; Fisher C; Parkinson MC
Am J Surg Pathol; 2006 Jan; 30(1):1-6. PubMed ID: 16330935
[TBL] [Abstract][Full Text] [Related]
24. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
[TBL] [Abstract][Full Text] [Related]
26. The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.
Chirieac LR; Pinkus GS; Pinkus JL; Godleski J; Sugarbaker DJ; Corson JM
Am J Cancer Res; 2011; 1(1):14-24. PubMed ID: 21969119
[TBL] [Abstract][Full Text] [Related]
27. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
28. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J
Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195
[TBL] [Abstract][Full Text] [Related]
29. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
30. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
32. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
33. Myxoid variant of peritoneal epithelioid malignant mesothelioma. A case report.
Goldová B; Dundr P; Zikán M; Tomancová V
Cesk Patol; 2014 Jul; 50(3):149-51. PubMed ID: 25186596
[TBL] [Abstract][Full Text] [Related]
34. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
[TBL] [Abstract][Full Text] [Related]
35. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
[TBL] [Abstract][Full Text] [Related]
36. Positive TTF-1 Expression in Malignant Mesothelioma: A Case Report.
Richter G; Heidersdorf H; Hirschfeld D; Krebbel F
Am J Case Rep; 2016 Mar; 17():133-6. PubMed ID: 26939861
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I
World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
40. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
Pu RT; Pang Y; Michael CW
Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
